BioCardia Files Request For FDA Meeting Related To Approval For CardiAMP System For Ischemic Chronic Heart Failure

BioCardia, Inc. (NASDAQ: BCDA) has submitted clinical study data for its CardiAMP System to the FDA and requested a meeting to discuss an accelerated approval pathway for treating ischemic chronic heart failure with reduced ejection fraction (HFrEF). The meeting is expected to occur this quarter under the FDA Breakthrough Designation for the CardiAMP System. Key objectives include obtaining FDA feedback on the proposed submission based on safety data and clinical responses from 125 trial participants.